La Jolla Pharmaceutical Revenue Growth Rates (LJPC), Current and Historic Growth - CSIMarket
CSIMarket Company Name, Ticker, Suppliers, else..
 


• Revenue Y/Y
• Op. Income Y/Y
• Cop. Income Y/Y
• Net Income Y/Y
• Eps Cop. Y/Y
• Eps Net Y/Y
• Free Cash Flow Y/Y
• Cash Flow Y/Y
• Capex Y/Y
• Sales Y/Y Annual
La Jolla Pharmaceutical Company  (NASDAQ: LJPC)
 

LJPC's Revenue Growth by Quarter and Year

La Jolla Pharmaceutical's Revenue results by quarter and year



Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.

LJPC Revenue (in millions $) FY 2022 FY 2021 FY 2020 FY 2019
4th Quarter December -
3rd Quarter September -
2nd Quarter June 10.54
1st Quarter March 10.43
FY 20.97





LJPC Revenue second quarter 2022 Y/Y Growth Comment
La Jolla Pharmaceutical Company reported fall in Revenue in the second quarter 2022 by -34.35% to $ 10.54 millions, from the same quarter in 2021.
The drop in the second quarter 2022 La Jolla Pharmaceutical Company's Revenue compares unfavorably to the Company's average Revenue jump of 46.59%.

Looking into second quarter 2022 results within Biotechnology & Pharmaceuticals industry 65 other companies have achieved higher Revenue growth. While La Jolla Pharmaceutical Company' s Revenue drop of -34.35% ranks overall at the positon no. 4106 in the second quarter 2022.


LJPC Revenue ( Y/Y Growth %) 2022
 2021 2020 2019
4th Quarter December - 11.51 % 51.03 % 73.44 %
3rd Quarter September - 46.75 % 58.84 % 64.55 %
2nd Quarter June -34.35 % 176.42 % 1.93 % 258.49 %
1st Quarter March -69.45 % 349.8 % 72.5 % 443.21 %
FY   - 126.57 % 44.93 % -

Financial Statements
La Jolla Pharmaceutical's second quarter 2022 Revenue $ 10.54 millions LJPC's Income Statement
La Jolla Pharmaceutical's second quarter 2021 Revenue $ 16.06 millions Quarterly LJPC's Income Statement


LJPC Revenue (Quarter on Quarter Growth %)

 2022
 2021 2020 2019
4th Quarter December - -8.26 % 20.73 % 26.97 %
3rd Quarter September - -17.12 % 56.11 % 0.18 %
2nd Quarter June 1.08 % -52.96 % -23.45 % 29.55 %
1st Quarter March -14.58 % 211.78 % 4.69 % 5.26 %
FY (Year on Year)   - 126.57 % 44.93 % -


Back to LJPC Growth rate Comparisons >> Back to LJPC Growth rate Comparisons >>


Revenue second quarter 2022 Y/Y Growth Company Ranking
Within: No.
Biotechnology & Pharmaceuticals Industry #66
Healthcare Sector #618
Overall #4106

Revenue Y/Y Growth Statistics
High Average Low
443.26 % 46.59 % -100 %
(Mar 31 2019)   (Dec 31 2017)
Revenue second quarter 2022 Y/Y Growth Company Ranking
Within: No.
Biotechnology & Pharmaceuticals Industry #66
Healthcare Sector #618
Overall #4106
Revenue Y/Y Growth Statistics
High Average Low
443.26 % 46.59 % -100 %
(Mar 31 2019)   (Dec 31 2017)

Revenue by Quarter for the Fiscal Years 2019, 2020, 2021, 2022

La Jolla Pharmaceutical's Q/Q Revenue Growth


Revenue Q/Q Growth Statistics
High Average Low
211.72 % 13.67 % -100 %
(Mar 31 2021)  


LJPC's II. Quarter Q/Q Revenue Comment
La Jolla Pharmaceutical Company achieved in the II. Quarter 2022 below company average Revenue growth of 1.08% quarter on quarter, to $ 10.54 millions.

II. Quarter 2022 Revenue Q/Q growth were paradoxical, although lower than the regular, yet it demonstrates absolute recovery measured to the -52.96% in the II. Quarter a year ago.

Within Biotechnology & Pharmaceuticals industry 58 other companies have achieved higher Revenue quarter on quarter growth. While La Jolla Pharmaceutical's Revenue growth quarter on quarter, overall rank is 2979.


Revenue Q/Q Growth Company Ranking
Within: No.
Biotechnology & Pharmaceuticals Industry #59
Healthcare Sector #469
Overall #2979
Revenue Q/Q Growth Company Ranking
Within: No.
Biotechnology & Pharmaceuticals Industry #59
Healthcare Sector #469
Overall #2979
Revenue Q/Q Growth Statistics
High Average Low
211.72 % 13.67 % -100 %
(Mar 31 2021)  


LJPC's II. Quarter Q/Q Revenue Comment
La Jolla Pharmaceutical Company achieved in the II. Quarter 2022 below company average Revenue growth of 1.08% quarter on quarter, to $ 10.54 millions.

II. Quarter 2022 Revenue Q/Q growth were paradoxical, although lower than the regular, yet it demonstrates absolute recovery measured to the -52.96% in the II. Quarter a year ago.

Within Biotechnology & Pharmaceuticals industry 58 other companies have achieved higher Revenue quarter on quarter growth. While La Jolla Pharmaceutical's Revenue growth quarter on quarter, overall rank is 2979.


La Jolla Pharmaceutical's 12 Months Revenue Growth Year on Year


Revenue TTM Growth

12 Months Ending
(Jun 30 2022)		 12 Months Ending
(Mar 31 2022)		 12 Months Ending
(Dec 31 2021)		 12 Months Ending
(Sep 30 2021)		 12 Months Ending
(Jun 30 2021)
Cumulative Revenue 12 Months Ending $ 46.49 $ 52.01 $ 75.72 $ 74.46 $ 70.22
Y / Y Revenue Growth (TTM) -33.79 % -13.27 % 126.58 % 150.56 % 166.47 %
Year on Year Revenue Growth Overall Ranking # 3441 # 2888 # 109 # 209 # 82
Seqeuential Revenue Change (TTM) -10.61 % -31.32 % 1.69 % 6.04 % 17.1 %
Seq. Revenue Growth (TTM) Overall Ranking # 1651 # 3363 # 1664 # 1362 # 2842


Cumulative Revenue growth Comment
La Jolla Pharmaceutical's cumulative 12 months Revenue continue to drop, but on the faster rate at -33.79% year on year, at Jun 30 2022 compare to the -13.27% decrease at Mar 31 2022. If the La Jolla Pharmaceutical's fiscal year would end at Jun 30 2022, annual Revenue would be $46 millions.

In the Healthcare sector 502 other companies have achieved higher trailing twelve month Revenue growth. While Revenue growth total ranking has deteriorated compare to previous quarter from 2888 to 3441.

Revenue TTM Y/Y Growth Company Ranking
Within: No.
Biotechnology & Pharmaceuticals Industry # 34
Healthcare Sector # 503
Overall # 3441

Revenue TTM Y/Y Growth Statistics
High Average Low
166.47 %
 80.79 %
-33.79 %
 


Revenue TTM Q/Q Growth Company Ranking
Within: No.
Industry # 34
Sector # 246
S&P 500 # 1651
Cumulative Revenue growth Comment
La Jolla Pharmaceutical's cumulative 12 months Revenue continue to drop, but on the faster rate at -33.79% year on year, at Jun 30 2022 compare to the -13.27% decrease at Mar 31 2022. If the La Jolla Pharmaceutical's fiscal year would end at Jun 30 2022, annual Revenue would be $46 millions.

In the Healthcare sector 502 other companies have achieved higher trailing twelve month Revenue growth. While Revenue growth total ranking has deteriorated compare to previous quarter from 2888 to 3441.


Revenue TTM Y/Y Growth Company Ranking
Within: No.
Biotechnology & Pharmaceuticals Industry # 34
Healthcare Sector # 503
Overall # 3441

Revenue TTM Y/Y Growth Statistics
High Average Low
166.47 %
80.79 %
-33.79 %
 


Revenue TTM Q/Q Growth Company Ranking
Within: No.
Industry # 34
Sector # 246
S&P 500 # 1651




Other Revenue Growth
Biotechnology & Pharmaceuticals Industry Revenue Growth Trends and Statistics
Healthcare Sector Revenue Growth Statistics
Revenue Growth Trends for overall market
LJPC's Revenue Growth Ratio versus Biotechnology & Pharmaceuticals Industry, Healthcare Sector and total Market
Highest Ranking Revenue Growth
Lowest Ranking Revenue Growth




Companies with similar Revenue drop for the quarter ending Jun 30 2022 within Healthcare SectorY/Y Change %Revenue for the quarter ending Jun 30 2022
Edwards Lifesciences Corporation-0.15%$ -0.153 millions
Chemed Corporation-0.18%$ -0.182 millions
Heska Corporation-0.39%$ -0.387 millions
Ati Physical Therapy Inc -0.45%$ -0.451 millions
Phenomex Inc -0.52%$ -0.519 millions
Organon and Co -0.63%$ -0.627 millions
Outset Medical Inc -0.63%$ -0.631 millions
Accuray Incorporated-0.82%$ -0.823 millions
Travere Therapeutics Inc -0.82%$ -0.824 millions
Elite Pharmaceuticals Inc -0.84%$ -0.835 millions
Amedisys Inc-1.11%$ -1.112 millions
Teleflex Incorporated-1.25%$ -1.252 millions
Embecta Corp -1.32%$ -1.322 millions
Y mabs Therapeutics inc -1.41%$ -1.406 millions
Organogenesis Holdings Inc -1.46%$ -1.457 millions
10x Genomics Inc -1.67%$ -1.672 millions
Mimedx Group Inc -1.88%$ -1.881 millions
Acorda Therapeutics Inc -2.31%$ -2.309 millions
Community Health Systems Inc -2.43%$ -2.428 millions
Alpha Pro Tech Ltd -2.43%$ -2.432 millions
Advanced Container Technologies Inc -2.54%$ -2.539 millions
Kamada Ltd -2.68%$ -2.678 millions
Fresenius Medical Care Ag-2.73%$ -2.730 millions
Orthofix Medical Inc -2.74%$ -2.738 millions
3m Company-2.77%$ -2.771 millions
Teva Pharmaceutical Industries Limited-3.17%$ -3.171 millions
Neurometrix Inc -3.40%$ -3.397 millions
Royalty Pharma Plc-3.43%$ -3.425 millions
Bio rad Laboratories Inc -3.47%$ -3.468 millions
Healthlynked Corp-3.63%$ -3.630 millions


About La Jolla Pharmaceutical Revenue Growth Rates (LJPC), Current and Historic Growth - CSIMarket Analysis

How we calculate this

This page is based on issuer-reported fundamentals and CSIMarket’s U.S. equities database (20+ years). Growth is computed using year-over-year (Y/Y), sequential, and trailing-twelve-month (TTM) methods.

What’s included here

Company: La Jolla Pharmaceutical Co (CIK 920465).

Source & verification

Last updated

  • Page updated:
  • Data lineage: SEC filings → XBRL parse → normalization CSIMarket.com Database → growth calculations.
  • Accession: 0001564590-22-029398
  • Figures are derived from filed reports and may be restated; numbers are subject to revision.

Sources: La Jolla Pharmaceutical Co’s SEC filings (XBRL/Inline XBRL) and CSIMarket.com’s normalization & QA processes.



Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.